Science Corporation has raised $230m to advance commercial activities for its Prima brain-computer interface (BCI) retinal implant for vision restoration.
The California-based company’s oversubscribed Series C financing round featured participation from investors including Lightspeed Venture Partners, Khosla Ventures, and Quiet Capital. The latest round brings Science’s total funds to date to around $490m since its founding in 2021.
Science’s Prima BCI consists of an ultra-thin microchip implanted under the retina and a visual processing computer worn on a patient’s waistband. Using augmented reality (AR) glasses that contain a video camera and are connected to the computer, artificial intelligence (AI) within the computer converts information into electrical signals. After passing through the retinal and optical nerve cells into the brain, the information is then interpreted as vision.
In October 2025, Science published results from its PRIMAvera pivotal trial (NCT04676854) in theNew England Journal of Medicine. Out of 38 patients with visual impairment due to dry age-related macular degeneration (dry AMD) who were implanted with Prima, the trial demonstrated that 84% of patients were able to read again once fitted with the BCI.
Following the trial’s results, Science submitted Prima BCI for regulatory approval in the EU and the US Food and Drug Administration (FDA). It now expects the BCI to launch in Europe later this year.
The latest funding will support these ongoing commercial efforts, along with the expansion of Science’s research, manufacturing, and operational infrastructure. The company also said the proceeds will support the continued advancement of its other products, including its Biohybrid neural interface technology and Vessel perfusion platform.
Science’s CEO, Max Hodak, commented: “By engaging the brain directly as an information processing organ, we are able to achieve much greater effect sizes and drive unprecedented clinical impact.
“We are deeply committed to research and new technologies that can provide treatment options where none existed before – and which will fundamentally change and improve lives.”
The rise of BCI technologies
GlobalData analysis reveals that the global neurology devices market is projected to reach a valuation above $25bn in 2034.
In healthcare, BCI technologies are on a rapid growth course. Morgan Stanley estimates there to be an early total addressable market (TAM) of $80bn across three million US adults for BCI technology, potentially reaching $320bn with further advancements.
BCI gained widespread attention in recent years due to Neuralink. In July 2025, reports emerged that the company, which is helmed by serial entrepreneur Elon Musk, expects to gain US Food and Drug Administration (FDA) approval for Telepathy, a BCI implant designed to give paralysed individuals the ability to control hardware such as computers and robotic limbs using only their thoughts, by 2029. By 2031, the company hopes to generate $1bn in revenue, dependant on success with the implantation of Telepathy and other of its BCI implants in 20,000 patients.
Other companies in the BCI space at earlier stages of clinical development include Synchron and InBrain Neuroelectronics, which are investigating BCI technology to address individuals with severe paralysis and Parkinson’s disease.
